Parkinson disease

Related Subjects: Multiple System Atrophy (MSA) |Parkinson Plus syndromes |Parkinsonism |Idiopathic Parkinson disease |Acutely Ill Patient with Parkinson's disease |Progressive Supranuclear Palsy |Drug Induced Parkinson disease |Neuroleptic Malignant Syndrome

🧠 Parkinson's Disease (PD) is a chronic, progressive neurological disorder affecting movement and non-motor functions. 👴 Most often seen in older adults, though genetic forms can present earlier.

ℹ️ About

• 🌀 Idiopathic PD: Tremor, rigidity, bradykinesia.
• 👵 More common in elderly, but younger onset with genetic variants.

🧬 Aetiology

• ⬇️ Dopaminergic neurons lost in the substantia nigra.
• ⚡ Disrupted communication in the basal ganglia.
• 🧩 Lewy bodies (α-synuclein inclusions) hallmark of PD pathology.

Pathology: Braak Staging

• 📈 Pathology spreads stepwise: brainstem → midbrain → cortex.
• 🚽 Early = constipation, REM sleep disorder; 🤲 Later = tremor, rigidity.

Genetics

• 🧬 PARK1 (α-synuclein): Early-onset, autosomal dominant.
• 🧬 PARK2 (parkin): Autosomal recessive, good response to L-Dopa.

🩺 Progressive Clinical Features

• ✋ Tremor: “Pill-rolling” resting tremor.
• 🐢 Bradykinesia: Slowness, difficulty initiating movement.
• 🪵 Rigidity: Limb stiffness, cogwheeling.
• ⚖️ Postural instability: Falls, poor balance.
• 🌙 Non-motor: depression, constipation, sleep disturbance, anosmia.

Stages of PD

• 1️⃣ Mild unilateral tremor.
• 2️⃣ Bilateral symptoms, slower movement.
• 3️⃣ Falls, significant motor difficulty.
• 4️⃣ Severe disability, daily assistance required.
• 5️⃣ Bedridden/wheelchair, hallucinations possible.

Diagnostic Imaging

• 🧲 MRI: Exclude mimics (vascular PD, NPH).
• 📊 DaT Scan: Differentiates PD from essential tremor.

Pharmacological Management

• 💊 Levodopa + Carbidopa (Sinemet): Gold standard, best for motor symptoms.
• 🟤 COMT inhibitors: Prolong levodopa action (e.g. entacapone).
• 🟢 Dopamine agonists: Ropinirole, pramipexole (younger patients).
• 🔵 MAO-B inhibitors: Rasagiline, selegiline (mild disease).
• 🟣 Anticholinergics: Tremor-dominant PD (younger patients).
• 🟡 Amantadine: Useful for dyskinesias.

🧠 About Parkinson’s Drug Management

• Parkinson’s disease results from dopamine deficiency in the basal ganglia, leading to tremor, rigidity, bradykinesia, and postural instability.
• The main goal of therapy is to restore dopaminergic tone, reduce motor and non-motor symptoms, and improve quality of life.
• Treatment strategies are individualised based on patient age, disease stage, cognitive function, frailty, and comorbidities.
• Combination therapy is often required as the disease progresses, and management should be supervised by a specialist in movement disorders.

💊 Main Drug Classes & Dosing

• 1️⃣ Levodopa + DDC inhibitor (co-careldopa, co-beneldopa)
  • Mechanism: Levodopa is converted to dopamine in the brain; carbidopa or benserazide blocks peripheral metabolism.
  • First-line in patients >70 years or with cognitive impairment.
  • Dose:
    • Start low (e.g. co-careldopa 12.5/50 mg TDS) and titrate gradually.
    • Typical maintenance: 50/200 mg TDS–QDS, adjusted to clinical response.
  • Modified formulations:
    • Rytary (IPX203): extended-release capsule for smoother “on” time.
    • LCIG (Duopa/Duodopa): intestinal gel via pump for continuous delivery.
    • Inhaled Levodopa (Inbrija): rescue option for sudden “off” episodes, onset within 10 minutes.
    • ND0612: subcutaneous infusion for 24-hour steady levels (emerging therapy).
  • ⚠️ Common side effects: dyskinesia, orthostatic hypotension, hallucinations, nausea, “on–off” fluctuations with long-term use.
• 2️⃣ Dopamine Agonists (pramipexole, ropinirole, rotigotine patch, apomorphine)
  • Mechanism: Directly stimulate dopamine receptors (mainly D2/D3), bypassing presynaptic neurons.
  • Use: Monotherapy in early PD for younger adults, or as add-on to levodopa in advanced disease.
  • Examples & Doses:
    • Pramipexole: 0.125 mg TDS → titrate to max 1.5 mg TDS.
    • Ropinirole: 0.25 mg TDS → increase; XL forms available for once-daily dosing.
    • Rotigotine patch: start 2 mg/24 h → titrate to max 16 mg/24 h.
    • Apomorphine: subcutaneous rescue injection or continuous infusion (specialist use only).
  • ⚠️ Side effects: impulse control disorders (gambling, hypersexuality), hallucinations, nausea, ankle oedema, sudden sleep attacks.
  • Note: Start low, titrate slowly, monitor mood and sleep; avoid abrupt withdrawal to prevent dopamine agonist withdrawal syndrome.
• 3️⃣ MAO-B Inhibitors (selegiline, rasagiline, safinamide)
  • Mechanism: Inhibit monoamine oxidase-B, decreasing dopamine breakdown in the brain.
  • Use: Early PD (as monotherapy) or adjunct therapy to prolong levodopa effect and reduce “off” episodes.
  • Dosing:
    • Selegiline: 5 mg OD or BD.
    • Rasagiline: 1 mg OD.
    • Safinamide: 50 mg OD → may increase to 100 mg OD.
  • ⚠️ Side effects: insomnia, headache, mild hallucinations; rare hypertensive crisis with tyramine-rich foods.
  • Note: Avoid combining with serotonergic antidepressants or opioids due to serotonin syndrome risk.
• 4️⃣ COMT Inhibitors (entacapone, opicapone, tolcapone)
  • Mechanism: Inhibit catechol-O-methyltransferase (COMT), prolonging levodopa’s half-life and “on” time.
  • Use: Always as adjunct to levodopa when wearing-off occurs.
  • Dosing:
    • Entacapone: 200 mg with each levodopa dose (max 10/day).
    • Opicapone: 50 mg once nightly (newer, long-acting).
    • Tolcapone: 100–200 mg TDS; effective but limited by hepatotoxicity.
  • ⚠️ Side effects: diarrhoea, urine discolouration (orange), dyskinesia, hepatotoxicity (tolcapone—monitor LFTs).
• 5️⃣ Amantadine
  • Mechanism: NMDA receptor antagonist; enhances dopamine release and reduces reuptake.
  • Dose: 100 mg OD–BD (max 300 mg/day); extended-release (Gocovri ER) once daily at bedtime.
  • Use: Helps control levodopa-induced dyskinesias and provides mild symptomatic benefit.
  • ⚠️ Side effects: hallucinations, livedo reticularis (mottled skin), ankle oedema, confusion, blurred vision.
  • Note: Dose reduction required in renal impairment and elderly patients.
• 6️⃣ Anticholinergics (trihexyphenidyl, procyclidine)
  • Mechanism: Block muscarinic receptors, restoring balance between dopamine and acetylcholine.
  • Dose: Trihexyphenidyl 1 mg OD–BD (max 15 mg/day); adjust slowly.
  • Use: Tremor-predominant PD in young, cognitively intact patients.
  • ⚠️ Side effects: confusion, memory impairment, urinary retention, constipation, dry mouth — avoid in elderly.
• 7️⃣ Adjunct & Emerging Agents
  • Adenosine A2A antagonist (Istradefylline): Adjunct to levodopa in patients with “off” episodes; reduces "off" time and improves mobility.
  • GLP-1 receptor agonists (Exenatide, Lixisenatide): Under investigation for neuroprotective and disease-modifying benefits.
  • Gene therapy (AADC vector, AXO-Lenti-PD): Experimental approaches to restore dopamine synthesis.

🧩 Key Points

• Levodopa remains the gold standard for symptomatic control.
• Long-acting and continuous delivery systems (LCIG, ND0612, Rotigotine patch) help minimize “off” time and fluctuation.
• Adjunct agents (MAO-B, COMT inhibitors, adenosine antagonists) prolong levodopa benefit.
• Tailor therapy to symptom pattern, lifestyle, and patient goals — avoid polypharmacy where possible.
• Monitor regularly for side effects such as dyskinesia, hallucinations, orthostatic hypotension, and impulse control disorders.

⚙️ Advanced / Rescue Therapies

• LCIG (Duopa/Duodopa): Continuous intrajejunal infusion for advanced PD with severe motor fluctuations.
• Apomorphine Pump: Delivers continuous dopamine agonist stimulation; used for complex “off” episodes.
• Inhaled Levodopa (Inbrija): Rapid rescue during sudden wearing-off; onset within 10 minutes.
• Deep Brain Stimulation (DBS): Non-pharmacologic option for selected patients unresponsive to medications.

✅ Summary

Parkinson’s disease management requires a stepwise, individualized approach. Start with levodopa-based therapy in older or cognitively impaired patients, and dopamine agonists or MAO-B inhibitors in younger individuals. Add COMT inhibitors or amantadine as the disease progresses to reduce fluctuations and dyskinesia. Advanced and long-acting formulations—both oral and infusion-based—are now enabling more stable motor control and improved quality of life.

Summary: Levodopa remains the most effective treatment for Parkinson’s disease. Long-acting and continuous infusion forms improve symptom stability, while adjuncts—such as dopamine agonists, MAO-B inhibitors, and COMT inhibitors—help control motor fluctuations. Therapy should always be individualized to minimize side effects and optimize quality of life.

📋 NICE Simplified Pathway

• 👴 Older (>70) or cognitive impairment → Levodopa.
• 🧑 Younger (<70), no cognitive issues → Dopamine agonist or MAO-B inhibitor.
• ⚡ Escalate stepwise with COMT inhibitors, dopamine agonists, or amantadine if fluctuations develop.
• Specialist referral at all treatment stages.

🚑 Management When Unable to Swallow (NBM)

• 💧 Dispersible levodopa (Madopar® dispersible): can be given via NG tube.
• 🩹 Rotigotine patch: provides continuous dopaminergic stimulation.
• 💉 Apomorphine (SC injection/infusion): specialist initiation, useful for acute rescue.
• 📡 Duodopa® (levodopa–carbidopa intestinal gel): continuous PEG-J infusion.
• ⚠️ Never stop dopaminergic drugs suddenly → risk of Parkinsonism–Hyperpyrexia Syndrome.

⚠️ Key Cautions & Monitoring

• Impulse control disorders (gambling, hypersexuality, binge eating) with dopamine agonists.
• Hallucinations & psychosis with dopaminergic drugs.
• Postural hypotension with levodopa and dopamine agonists.
• Monitor LFTs with tolcapone.
• Adjust doses in renal impairment for amantadine.

Surgical

• 🧩 Deep Brain Stimulation (DBS): For advanced disease, subthalamic nucleus/globus pallidus targets.

Multidisciplinary Care

• 👩‍⚕️ Nurse specialist: medication timing, education.
• 🏃 Physiotherapy: balance, gait training.
• 🗣️ SLT: dysarthria, dysphagia.
• 🛠️ OT: adaptive aids, safety at home.

Hospital/Acute Considerations

• ⏰ Never delay PD meds (risk of severe deterioration, even NBM use NG or rotigotine patch).
• 🚫 Avoid antidopaminergic drugs (metoclopramide, haloperidol, prochlorperazine).

Non-Motor Complications

• 🚽 Constipation → macrogol, fluids, mobility.
• 📉 Orthostatic hypotension → fludrocortisone, midodrine.
• 🦠 Recurrent UTIs → hydration, constipation prevention.
• 👻 Psychosis/hallucinations → quetiapine, clozapine.
• 🧩 Dementia → rivastigmine (watch for tremor worsening).

Advance Care Planning

• 📝 Advance directives, lasting power of attorney.
• 🤝 Signposting to community support and respite care.

References

• Visanji et al. Acta Neuropathologica Comms 2013

Cases — Parkinson’s Disease with Complications

• Case 1 — Motor Fluctuations (“Wearing Off”) ⏳: A 68-year-old man on levodopa for 7 years reports that tremor and rigidity return 3 hours after each dose. He experiences “on–off” fluctuations through the day. Complication: Motor fluctuations due to long-term levodopa use. Management: Shorten levodopa dosing intervals; add COMT inhibitor (entacapone) or dopamine agonist.
• Case 2 — Dyskinesias 💃: A 62-year-old woman develops involuntary writhing movements of her trunk and arms about 30 minutes after each levodopa dose. Complication: Levodopa-induced dyskinesia. Management: Lower levodopa dose; add amantadine; consider deep brain stimulation if severe.
• Case 3 — Parkinson’s Disease Dementia 🧠: A 75-year-old man with 10 years of PD develops progressive memory loss, visual hallucinations, and difficulty with daily tasks. Complication: Parkinson’s disease dementia. Management: Rivastigmine (first-line cholinesterase inhibitor); review dopaminergic drugs that worsen hallucinations.
• Case 4 — Autonomic Dysfunction 💧: A 70-year-old woman with PD reports frequent faints on standing, constipation, and urinary urgency. BP falls from 135/80 supine to 95/60 standing. Complication: Autonomic dysfunction (orthostatic hypotension, bladder involvement). Management: Non-pharmacological (slow position changes, compression stockings, ↑ salt/fluid); consider fludrocortisone or midodrine.
• Case 5 — Impulse Control Disorder 🎰: A 60-year-old man on pramipexole for PD develops compulsive gambling and hypersexuality, which his wife finds distressing. Complication: Dopamine agonist–induced impulse control disorder. Management: Reduce/stop dopamine agonist; switch to levodopa-based regimen; behavioural support.

Teaching Commentary 🧠

Parkinson’s disease complications can be divided into: - Motor: fluctuations (“wearing off”), dyskinesias. - Neuropsychiatric: dementia, hallucinations, depression, impulse control disorders. - Autonomic: postural hypotension, constipation, bladder dysfunction, erectile dysfunction. - Sleep: REM sleep behaviour disorder, insomnia. Complications often reflect both disease progression and treatment side effects. Management requires balancing dopaminergic therapy, adding adjuncts (COMT/MAO-B inhibitors), and addressing non-motor symptoms with MDT support. Deep brain stimulation is an option in selected patients with refractory motor fluctuations.